SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Where GI practices are struggling, succeeding (Becker’s GI & Endoscopy)
- Physician shortage and private equity: the ruin of U.S. health care (KevinMD)
- Why leading physicians will move to concierge medicine in 2026 with Greg Grant of Specialdocs (Physicians Practice)
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy (Nature)
- Stiffer colon could signal risk of early-onset colorectal cancer (Medical Xpress)
- Successful GI Sign-off Protocol Incorporates Primary Care Feedback (GI & Endoscopy News)
- Earlier and More Intensive Advanced Therapy Use Fails to Improve 10-Year Crohn’s Outcomes (Docwire News)
- CMS Launches WISeR Model: New Medicare Prior Authorization Rules Start Jan. 1 (HIT Consultant)
